JP2024506384A - ロフルミラストの眼科的送達方法 - Google Patents

ロフルミラストの眼科的送達方法 Download PDF

Info

Publication number
JP2024506384A
JP2024506384A JP2023548873A JP2023548873A JP2024506384A JP 2024506384 A JP2024506384 A JP 2024506384A JP 2023548873 A JP2023548873 A JP 2023548873A JP 2023548873 A JP2023548873 A JP 2023548873A JP 2024506384 A JP2024506384 A JP 2024506384A
Authority
JP
Japan
Prior art keywords
roflumilast
administration
cornea
patient
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506384A5 (cg-RX-API-DMAC7.html
Inventor
チョウドリ,バスカー
グカスヤン,ホヴハンネス・ジョン
Original Assignee
イオリクス セラピューティクス,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イオリクス セラピューティクス,インコーポレーテッド filed Critical イオリクス セラピューティクス,インコーポレーテッド
Publication of JP2024506384A publication Critical patent/JP2024506384A/ja
Publication of JP2024506384A5 publication Critical patent/JP2024506384A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023548873A 2021-02-10 2022-02-10 ロフルミラストの眼科的送達方法 Pending JP2024506384A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163148008P 2021-02-10 2021-02-10
US63/148,008 2021-02-10
US202163261404P 2021-09-20 2021-09-20
US63/261,404 2021-09-20
PCT/US2022/015942 WO2022173923A1 (en) 2021-02-10 2022-02-10 Methods for ophthalmic delivery of roflumilast

Publications (2)

Publication Number Publication Date
JP2024506384A true JP2024506384A (ja) 2024-02-13
JP2024506384A5 JP2024506384A5 (cg-RX-API-DMAC7.html) 2025-02-19

Family

ID=82704332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548873A Pending JP2024506384A (ja) 2021-02-10 2022-02-10 ロフルミラストの眼科的送達方法

Country Status (8)

Country Link
US (2) US12102622B2 (cg-RX-API-DMAC7.html)
EP (1) EP4291162A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506384A (cg-RX-API-DMAC7.html)
AU (1) AU2022218993A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206106A1 (cg-RX-API-DMAC7.html)
IL (1) IL304924A (cg-RX-API-DMAC7.html)
MX (1) MX2023009352A (cg-RX-API-DMAC7.html)
WO (1) WO2022173923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12263160B2 (en) * 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
AR130498A1 (es) * 2022-09-16 2024-12-11 Iolyx Therapeutics Inc Composiciones farmacéuticas de alta concentración de roflumilast para administración oftálmica
AU2024298631A1 (en) * 2023-07-25 2026-02-05 Iolyx Therapeutics, Inc. Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017527A1 (en) * 1999-09-06 2001-03-15 Ono Pharmaceutical Co., Ltd. Preventive and therapeutic agents for eye diseases
JP2002241265A (ja) * 2001-02-16 2002-08-28 Nof Corp 点眼用水性懸濁製剤およびその製造方法
JP2005529930A (ja) * 2002-05-28 2005-10-06 アルタナ ファルマ アクチエンゲゼルシャフト 局所適用可能な薬剤学的製剤
JP2007016024A (ja) * 2005-06-09 2007-01-25 Santen Pharmaceut Co Ltd ロフルミラスト点眼液
JP2014533302A (ja) * 2011-11-15 2014-12-11 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンa2型の懸濁剤

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
IL160271A0 (en) 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing pde4-inhibitors and nsaid
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
SI1885336T1 (sl) 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
AU2006244245B2 (en) 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
WO2006132342A1 (ja) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
CN103508936A (zh) 2008-08-22 2014-01-15 赛诺菲-安万特 用于制备吲哚苄胺化合物的中间体
MX2012006401A (es) 2009-12-03 2012-07-10 Lupin Ltd Proceso para preparar composiciones oftalmicas farmaceuticas.
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1214159A1 (zh) 2012-11-08 2016-07-22 Rhizen Pharmaceuticals S.A. 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
WO2020081622A1 (en) 2018-10-16 2020-04-23 Research Triangle Institute Subcutaneous biodegradable reservoir device
EP4061332A4 (en) 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR
US12263160B2 (en) * 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017527A1 (en) * 1999-09-06 2001-03-15 Ono Pharmaceutical Co., Ltd. Preventive and therapeutic agents for eye diseases
JP2002241265A (ja) * 2001-02-16 2002-08-28 Nof Corp 点眼用水性懸濁製剤およびその製造方法
JP2005529930A (ja) * 2002-05-28 2005-10-06 アルタナ ファルマ アクチエンゲゼルシャフト 局所適用可能な薬剤学的製剤
JP2005529928A (ja) * 2002-05-28 2005-10-06 アルタナ ファルマ アクチエンゲゼルシャフト 眼の病気を治療するためのロフルミラストの眼科的使用
JP2007016024A (ja) * 2005-06-09 2007-01-25 Santen Pharmaceut Co Ltd ロフルミラスト点眼液
JP2014533302A (ja) * 2011-11-15 2014-12-11 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンa2型の懸濁剤

Also Published As

Publication number Publication date
IL304924A (en) 2023-10-01
US20220249451A1 (en) 2022-08-11
WO2022173923A1 (en) 2022-08-18
US20250009724A1 (en) 2025-01-09
CA3206106A1 (en) 2022-08-18
US12102622B2 (en) 2024-10-01
EP4291162A1 (en) 2023-12-20
AU2022218993A1 (en) 2023-08-03
MX2023009352A (es) 2023-08-16
EP4291162A4 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
US20220184057A1 (en) Combination treatment of ocular inflammatory disorders and diseases
US20250009724A1 (en) Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) Methods of treating ocular inflammatory diseases
EA034839B1 (ru) Офтальмологический раствор
US20250255809A1 (en) Ophthalmic pharmaceutical compositions of roflumilast
CN118384160A (zh) 用于控制和/或降低近视发展的药物组合物
EP2765988B1 (en) Ocular composition containing bromfenac with increased bioavailability
US20160051526A1 (en) The Local Treatment of Inflammatory Ophthalmic Disorders
TW201400117A (zh) 使用拉喹莫德治療眼發炎疾病
JP6522592B2 (ja) 1h−インドール−1−カルボキサミド誘導体を含有する局所水性眼科用組成物および眼疾患の治療へのその使用
JP2009519962A (ja) 眼投与用局所メカミルアミン製剤およびその使用
US20250032468A1 (en) Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases
HK40101566A (en) Methods for ophthalmic delivery of roflumilast
US20260083712A1 (en) Methods for treating patients with ocular comorbidities of an autoimmune disorder
US20250339419A1 (en) Methods of treating ocular inflammatory diseases
HK40113755A (en) Methods of treating ocular inflammatory diseases
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
US20160095861A1 (en) Ophthalmic ointments comprising valganciclovir hydrochloride for treating infective eye diseases
CA3014071A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
US20140213605A1 (en) Methods for treating eye disorders using opioid receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260615